🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ddAC vs q3wAC regimen in patients with TNBC treated with pembrolizumab plus CT in the neoadjuvant setting - Romualdo Barroso, MD PhD Triple Negative Breast Cancer Foundation oncodaily.com/url/127085 #Cancer #Oncology #OncoDaily #CancerPrevention #NeoadjuvantSetting #TNBC

Neoadjuvant Immunotherapy—From Trials to Practice out on JAMA Oncology by Dr. E Mittendorf and our @oncoAlert #BreastCancer Faculty Sara Tolaney of Dana-Farber 🇺🇸 Immunotherapy, particularly immune checkpoint♟️ inhibition, has become a key🔑component of #cancer treatment, with approvals

Dr Komal Jhaveri lecturing on the future of ER+ MBC in the Brazilian Society of Clinical Oncology- thank you for all your work on the field SBOC

Thank you Dr Rita Nanda for your kindness and for sharing so much knowledge with us in the Annual Meeting of the Brazilian Society of Clinical Oncology SBOC

O GBECAM completará 20 anos em 2025, fruto da iniciativa de três brilhantes oncologistas: José Bines, Carlos Barrios e Sergio Simon. Este ano teremos o primeiro FIP GBECAM. Fiquem atentos aos prazos do edital! Luciana Landeiro, MD PhD Renata Colombo Bonadio, MD Romualdo Barroso, MD PhD

Fernanda Torres x Governors Awards. Photography: Sami Drasin

#SABCS24 POSTER SESSION | P3-09-19 | Tumor genomics in young patients with #MetastaticBreastCancer. #KristenBrantley Romualdo Barroso, MD PhD Brittany Bychkovsky, MD Tari King MD Sara Tolaney Ann Partridge MD, MPH Nancy Lin, MD #AnaGarridoCastro

#SABCS24 📍Dose-dense AC associated with higher RCB 0-1 rate compared to q3w AC during neoadjuvant CT+pembro for TNBC 📍Neo-Real study Laura Testa Romualdo Barroso, MD PhD Debora Gagliato Daniele Assad Suzuki GBECAM OncoAlert

Emocionante!

Wow. I am so grateful for our BC community for supporting our good friend and colleague ⁦Aditya Bardia, MD⁩ and his family during this terrible time. Please donate!! Fundraiser by Mina Sedrak : Support the Bardia Family After Palisades Fire. gofundme.com/f/bardia

📣Jovenes oncologos de LATAM a no perderse el preceptorship de ESMO - Eur. Oncology que se llevará a cabo el 9 y 10 de abril 📆 antes del #ESMOSummit en Lima 🇵🇪 esmo.org/meeting-calend…

Congrat Sara! Well deserved Sara Tolaney

📢📢📢Jovenes oncologos de latinoamerica 🇦🇷🇺🇾🇨🇱🇧🇷🇨🇴🇵🇪🇪🇨🇵🇾🇧🇴🇲🇽🇨🇷🇵🇦🇬🇹🇳🇮 🇻🇪🇩🇴gran oportunidad para participar del Congreso de ESMO - Eur. Oncology Breast en Munich 🇩🇪!!! Convocatoria abierta para presentar casos y si es elegido beca de asistencia! Los esperamos con Rodrigo Sánchez-Bayona Angelika Starzer

Now is oficial Dr. Sara Tolaney will present the primary results of DB09 on June 2nd at Hall D1 at 7:30am #asco25

Another one for Dr Sara Tolaney She will be presenting the primary results of ASCENT-04 at ASCO 2025 - on May 31st at HALL B1 in the afternoon Dana-Farber’s Breast Oncology Center Dana-Farber ASCO #tnbc #immunotherapy #sacituzumabgovitecan #ASCO25

The NIMBUS trial of nivo-ipi for TMB-high MBC, led by Romualdo Barroso, MD PhD, now published in Nature Communications. Among 30 pts (most with HR+/HER2- dz), ORR was 20%, though the 6 pts with TMB >14 had ORR 60% & PFS 9.5 months. Safety profile favorable (ipi given low dose). nature.com/articles/s4146…

Happy to share this review in small, node-negative breast cancer published in npj breast, with some of my greatest mentors! rdcu.be/emkjN

Thank you Romualdo Barroso, MD PhD and all the DFCI team

Dr Sara Tolaney presenting data of ASCENT-04 with the new 1st line treatment for patients with #TNBC for patients with metastatic PD-L1 positive breast cancer Sara Tolaney Dana-Farber’s Breast Oncology Center

Excellent #ASCO25 infographic highlighting the results of the DESTINY-Breast09 study: 👉Participants in the #TDXd + #Pertuzumab arm lived longer without their disease growing, spreading, or getting worse compared with participants in the THP (taxane + trastuzumab + pertuzumab)